Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs KTP-001 (Primary)
- Indications Intervertebral disc displacement
- Focus Adverse reactions
- Sponsors Teijin
- 29 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2018.
- 29 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 08 May 2014 Planned number of patients changed from 32 to 24 as reported by ClinicalTrials.gov record.